The need for new strategies for treating HIV-1 infection has led to the development of a number of new drugs. The aim of this article is to review the latest results of clinical trials of dolutegravir, an integrase inhibitor whose efficacy, tolerability and safety have been confirmed in treatment-naive and treatment-experienced patients. The findings, together with its high genetic barrier and limited interactions with other drugs, indicate that dolutegravir will play an important role in the future treatment of HIV infection.
Dolutegravir: A new option for HIV treatment / Carbone, Alessia; Lazzarin, Adriano; Castagna, Antonella. - In: FUTURE VIROLOGY. - ISSN 1746-0794. - 9:9(2014), pp. 801-810. [10.2217/fvl.14.68]
Dolutegravir: A new option for HIV treatment
LAZZARIN, ADRIANOSecondo
;CASTAGNA, ANTONELLAUltimo
2014-01-01
Abstract
The need for new strategies for treating HIV-1 infection has led to the development of a number of new drugs. The aim of this article is to review the latest results of clinical trials of dolutegravir, an integrase inhibitor whose efficacy, tolerability and safety have been confirmed in treatment-naive and treatment-experienced patients. The findings, together with its high genetic barrier and limited interactions with other drugs, indicate that dolutegravir will play an important role in the future treatment of HIV infection.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
